Advertisement

Allogeneic Transplantation of Hematopoietic Stem Cells

  • Jacek Wachowiak
Chapter
Part of the Principles and Practice book series (PRINCIPLES)

Abstract

Molecular and cytometric studies of human hematopoietic stem cells and its microenvironment have greatly contributed to a better understanding of their biology, including regulation of their function and mutual interaction. This has resulted in the improvements of the procedure of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematological malignancies. In addition, molecular and cytometric studies enable better recognition of the pathology of toxic, immunological, and infectious complications related to allo-HSCT as well as better monitoring of post-transplant leukemia/lymphoma remission. Thereby, not only more effective prevention and early diagnosis of transplant-related complications, but also prompt diagnosis of imminent post-transplant leukemia/lymphoma relapse became possible. This, in turn, enables a preemptive treatment and precise evaluation of the response to the treatment. Finally, the long-term results of allo-HSCT for hematological malignancies systematically improve.

Keywords

Hematopoietic Stem Cell Minimal Residual Disease Conditioning Regimen Acute GvHD Allogeneic Hematopoietic Stem Cell Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Akashi K, Traver D, Kondo M, Weissman IL (1999) Lymphoid development from hematopoietic stem cells. J Hematol 69:217–226Google Scholar
  2. Akashi K, Traver D, Miyamoto T, Weissman IL (2000) A clonogenic common myeloid progenitor that gives rise to myeloid lineages. Nature 404:193–197PubMedCrossRefGoogle Scholar
  3. Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Theoret Y, Champagne MA, Krajinovic M (2010) Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transpl 45:262–267CrossRefGoogle Scholar
  4. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A; ALL-REZ BFM Study Group (2009) Prognostic value of minimal residual disease quantification before allogeneic stem cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 27:377–384Google Scholar
  5. Bader P, Willasch A, Klingebiel T (2008) Monitoring of post-transplant remission of childhood malignancies: is there a standard ? Bone Marrow Transpl 42(Suppl. 2):S31–S34CrossRefGoogle Scholar
  6. Ball LM, Bernardo ME, Locatelli F, Egeler RM (2008) Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT. Bone Marrow Transpl 42:S60–S66CrossRefGoogle Scholar
  7. Blank U, Karlsson G, Karlsson S (2008) Signaling pathways governing stem-cell fate. Blood 111:492–503PubMedCrossRefGoogle Scholar
  8. Bochud PY, Calandra T (2009) A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation. Clin Infect Dis 49:733–735PubMedCrossRefGoogle Scholar
  9. Bogunia-Kubik K, Gieryng A, Dłubek D, Lange A (2006a) The presence of the SDF-1-3′A allele is associated with a higher field of CD34+ mobilization in healthy donors donated PBPC for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 37(Suppl. 1):S218Google Scholar
  10. Bogunia-Kubik K, Wysoczanska B, Lange A (2006b) Non-HLA gene polymorphisms and the outcome of allogeneic hematopoietic stem cell transplantation. Curr Stem Cell Res Ther 1:239–253PubMedCrossRefGoogle Scholar
  11. Cardenas PA, Huang Y, Ildstad ST (2011) The role of pDC, recipient Treg and donor Treg in HSC engraftment. Mechanism of facilitation. Chimerism 2(3):65–70PubMedCrossRefGoogle Scholar
  12. Carreras E (2008) Early complications after HSCT. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds) Haematopoietic stem cell transplantation. ESH & EBMT, Paris, pp 181–196Google Scholar
  13. Choi SW, Levine JE, Ferrara JL (2010) Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 30:75–101PubMedCrossRefGoogle Scholar
  14. Coppell JA, Brown SA, Perry DJ (2003) Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 17:63–70PubMedCrossRefGoogle Scholar
  15. Cordonnier C (2008) Infections after HSCT. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds) Haematopoietic stem cell transplantation. ESH & EBMT, Paris, pp 199–217Google Scholar
  16. Devergie A (2008) Graft versus host disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds) Haematopoietic stem cell transplantation. ESH & EBMT, Paris, pp 219–234Google Scholar
  17. Dickinson AM (2008) Non-HLA genetics and predicting outcome in HSCT. Int J Immunogenet 35:375–380PubMedCrossRefGoogle Scholar
  18. Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H, Efrati E (2010) Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer 55:1172–1179PubMedCrossRefGoogle Scholar
  19. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11:945–956CrossRefGoogle Scholar
  20. Giebel S, Giorgiani G, Martinetti M, Zecca M, Maccario R, Salvaneschi L, Holowiecki J, Locatelli F (2003) Low incidence of severe acute graft-versus-host disease in children given hematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transpl 31:987–993CrossRefGoogle Scholar
  21. Giralt S (2005) Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? Hematology Am Soc Hematol Educ Program 2005:384–389 CrossRefGoogle Scholar
  22. Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, Zander AR, Ehninger G, Kröger N (2007) Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res 27:4377–4380PubMedGoogle Scholar
  23. Gorczyńska A, Turkiewicz D, Toporski J, Kałwak K, Rybka R, Ryczan R, Sajewicz L, Chybicka A (2004) Prompt initiation of immunotherapy with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children. Bone Marrow Transpl 33:211–217CrossRefGoogle Scholar
  24. Gratwohl A (2008) Principles of conditioning. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds) Haematopoietic stem cell transplantation. ESH & EBMT, Paris, pp 129–144Google Scholar
  25. Hansen JA, Chien JW, Warren EH, Zhao LP, Martin PJ (2010) Defining genetic risk for graft-versus-host disease and mortality following allogeneic stem cell transplantation. Curr Opin Hematol 17:483–492PubMedCrossRefGoogle Scholar
  26. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JM, Hackett NR, Quitoriano MS, Crystal RG, Rafii S, Moore MA (2001) Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic and stem cell. Blood 97:3354–3360PubMedCrossRefGoogle Scholar
  27. Hows JM, Passweg JR, Tichelli A, Locasciulli A, Szydlo R, Bacigalupo A, Jacobson N, Ljungman P, Cornish J, Nunn A, Bradley B, Socié G, IMUST Study Participating Centers; Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2006) Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transpl 38:799–805Google Scholar
  28. Jacobsohn DA (2008) Acute graft-versus host disease in children. Bone Marrow Transpl 41:215–221CrossRefGoogle Scholar
  29. Kessans MR, Gatesman ML, Kockler DR (2010) Plerixafor: a peripheral blood stem mobilizer. Pharmacotherapy 30:485–492PubMedCrossRefGoogle Scholar
  30. Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS (2010a) NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part i: methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transpl 16:1187–1211CrossRefGoogle Scholar
  31. Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS (2010b) NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part ii: chronic leukemias, myeloproliferative neoplasms and lymphoid malignancies. Biol Blood Marrow Transpl 16:1325–1346CrossRefGoogle Scholar
  32. Lam BS, Adams GB (2010) Hematopoietic stem cell lodgment in the adult bone marrow stem cell niche. Int J Lab Hematol 32:551–558. doi: 10.1111/j.1751-553X.2010.01250.x PubMedCrossRefGoogle Scholar
  33. Lang P, Handgretinger R (2008) Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transpl 42(Suppl. 2):S54–S59CrossRefGoogle Scholar
  34. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D, European Group for Blood and Marrow Transplantation (2010) Allogeneic and autologous transplantation for haematological diseases, solid tumors and immune disorders: current practice in Europe 2009. Bone Marrow Transpl 45:219–234Google Scholar
  35. Loeffler J, Ok M, Morton OC, Mezger M, Einsele H (2010) Genetic polymorphisms in the cytokine and chemokine system: their possible importance in allogeneic stem cell transplantation. Curr Top Microbiol Immunol 341:83–96PubMedCrossRefGoogle Scholar
  36. Majka M, Ratajczak MZ (2006) Biological role of the CXCR4-SDF-1 axis in normal human hematopoietic cells. Methods Mol Biol 332:103–114PubMedGoogle Scholar
  37. Martin-Antonio B, Granell M, Urbano-Ispizua A (2010) Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation. Expert Rev Hematol 3:411–427PubMedCrossRefGoogle Scholar
  38. Mattsson J, Ringdén O, Storb R (2008) Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl 14(11):165–170CrossRefGoogle Scholar
  39. Mehta J (2005) Cytokines in hematopoietic stem cell transplantation. Cancer Treat Rev 126:333–351CrossRefGoogle Scholar
  40. Miano M, Labopin M, HartmannO, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G; Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (2007) Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl 39:89–99Google Scholar
  41. Milosevic S, Bachnick B, Karim K, Bornkamm GW, Witter K, Gerbitz A, Mautner J, Behrends U (2010) Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation. Transplantation 90:1030–1035PubMedCrossRefGoogle Scholar
  42. Molofsky AV, Pardal R, Morisson SJ (2006) Diverse mechanism regulate stem cell self-reneval. Curr Opin Cell Biol 16:700–707CrossRefGoogle Scholar
  43. Mullighan CG (2006) Petersdorf EW (2006) Genomic polymorphism and allogeneic hematopoietic transplantation outcome. Biol Blood Marrow Transpl 12(1):19–27CrossRefGoogle Scholar
  44. Mullighan CG, Heatley S, Doherty K, Szabo F, Grigg A, Hughes TP, Schwarer AP, Szer J, Tait BD, Bik To L, Bardy PG (2002) Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 99:3524–3529PubMedCrossRefGoogle Scholar
  45. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polaryzing program in dendritic cells. Nat Immunol 6:769–776PubMedCrossRefGoogle Scholar
  46. Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stroma cells. Blood 110:3499–3506PubMedCrossRefGoogle Scholar
  47. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3:687–94PubMedCrossRefGoogle Scholar
  48. Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ, Holler E, Pihusch R (2004) Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 78:911–918PubMedCrossRefGoogle Scholar
  49. Plantinga TS, van der Velden WJ, Ferwerda B, van Spriel AB, Adema G, Feuth T, Donnelly JP, Brown GD, Kullberg BJ, Blijlevens NM, Netea MG (2009) Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 49:724–732PubMedCrossRefGoogle Scholar
  50. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ (2008) Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transpl 15(1):62–71CrossRefGoogle Scholar
  51. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva WA Jr, Latouche A, Devergie A, Esperou H, Ribaud P, Socie G, Zago MA, Gluckman E (2002) Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 100:3908–3918PubMedCrossRefGoogle Scholar
  52. Rosu-Myles M, Bhatia M (2003) SDF-1 enhances the expansion and maintenance of highly purified human hematopoietic progenitors. Hematol J 4:137–145PubMedCrossRefGoogle Scholar
  53. Ruscetti FW, Akel S, Bartelmez SH (2005) Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. Oncogene 24:5751–5763PubMedCrossRefGoogle Scholar
  54. Satwani P, Cooper N, Rao K, Veys P, Amrolia P (2008) Reduced intensity conditioning and allogeneic stem cell transplantation In childhood malignant and nonmalignant diseases. Bone Marrow Transpl 41:173–182CrossRefGoogle Scholar
  55. Scadden DT (2006) The stem-niche as an entity of action. Nature 441:1075–1079PubMedCrossRefGoogle Scholar
  56. Schroder NW, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5:156–164PubMedGoogle Scholar
  57. Szczepanski T (2007) Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 21:622–626PubMedGoogle Scholar
  58. Teshima T, Wynn TA, Soiffer RJ, Matsuoka K, Martin PJ (2008) Chronic graft-versus-host disease: How can we release Prometheus? Biol Blood Marrow Transpl 14:142–150CrossRefGoogle Scholar
  59. Vettenranta K, EBMT Paediatric Working Party (2008) Current European practice in pediatric myeloablative conditioning. Bone Marrow Transpl 41:S14–S17CrossRefGoogle Scholar
  60. Wodnar-Flipowicz A (2008) Biological properties of haematopoietic stem cells. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds) red. Hematopoietic stem cell transplantation. ESH & EBMT, Paris 34–44Google Scholar
  61. Youn BS, Mantel C, Broxmeyer HE (2000) Chemokines, chemokine receptors and hematopoiesis. Immunol Rev 177:150–174PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Pediatric Oncology, Hematology and TransplantologyPoznań University of Medical SciencesPoznańPoland

Personalised recommendations